#USA #Nashville #Veeva Systems #Sarah Cannon #Oncology Trials

Veeva Systems and Sarah Cannon Research Institute Form Strategic Collaboration

In a significant development for the oncology research landscape, Veeva Systems (NYSE: VEEV) has partnered with the Sarah Cannon Research Institute (SCRI) to enhance the efficiency and speed of clinical trials across more than 200 research locations. This collaboration was officially announced on June 4 in Barcelona, Spain, and it aims to leverage Veeva's Clinical Platform to unify SCRI's contract research organization (CRO) and site management organization (SMO) onto a seamless, single platform. This strategic integration not only streamlines operations but also facilitates improved data flow between clinical teams and research sites, creating a more integrated approach to clinical trial management.

SCRI's chief information and digital officer, Yazhene Krishnaraj, expressed enthusiasm for this integration, stating, "We are thrilled to advance our clinical trials by incorporating Veeva Clinical Platform into our digital toolkit." The collaboration is expected to empower SCRI's clinical teams to deliver innovative therapies to patients with greater precision and speed. This is an exciting evolution for SCRI, which has established itself as a leader in oncology trials, having conducted over 850 first-in-human studies that played a crucial role in the approval of numerous cancer therapies by the FDA in the last decade.

A Revolutionary Approach to Clinical Trials

Veeva’s Clinical Platform is a comprehensive tool that encompasses a wide range of clinical operations and data applications, designed to streamline every stage of clinical trials—from initiation to closure. This interconnected framework includes critical components such as Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and various other elements that simplify and standardize trial processes. By automating key functions, SCRI will provide better support to its sites, facilitating faster and more cost-effective trials.

Jim Reilly, president of Veeva Development Cloud, remarked on the nature of this groundbreaking partnership, saying, "We're excited to work closely with SCRI to drive innovation in oncology research… By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials." This approach will not only improve operational efficiency but is also expected to encourage more robust data collection and sharing, which are crucial for advancing clinical research.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute stands out among the global leaders in oncology research and community-based clinical trials. With a focus on bringing advanced therapies to patients for over thirty years, SCRI has built a vast network of over 1,300 physicians committed to enrolling patients in clinical trials throughout more than 200 locations across 20 states in the U.S. As a pivotal player in drug development, SCRI is dedicated to progressing oncology treatments and has consistently been at the forefront of research that leads to new FDA-approved therapies.

Veeva Systems: A Commitment to Life Sciences

As a global leader in cloud-based software solutions tailored for the life sciences sector, Veeva Systems is dedicated to innovation and excellence. With more than 1,000 customers that range from prominent biopharmaceutical firms to startup biotech companies, Veeva’s focus remains firmly on enhancing customer success and adapting to the ever-evolving needs of the industry. As a Public Benefit Corporation, Veeva strives to balance the interests of all stakeholders, ensuring that its products not only meet industry demands but also promote broader societal benefits.

In essence, the partnership between Veeva Systems and Sarah Cannon Research Institute represents a transformative step towards redefining the landscape of oncology clinical trials, making them more efficient, streamlined, and ultimately, more beneficial for the patient communities they aim to serve. This collaboration heralds a new era in clinical research, where technology and innovation work hand-in-hand to accelerate the development of groundbreaking therapies for cancer patients worldwide.